PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma

Asha Kandathil, Rathan M. Subramaniam

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Skeletal and soft tissue sarcomas need early and accurate diagnosis, staging, and treatment for optimal outcome. 18F-FDG PET/computed tomography (CT) is indicated in staging of patients with high-grade sarcomas and acts as a surrogate marker of histopathologic grade, guiding biopsy to most aggressive portion of the tumor. Pretherapy and posttherapy 18F-FDG PET/CT metabolic parameters are reliable indicators of survival in patients with sarcoma with an important role in posttreatment response assessment, enabling the treatment plan to be modified in nonresponders. 18F-FDG PET/CT is particularly useful in the evaluation of molecular targeted therapies, which induce metabolic change before structural change.

Original languageEnglish (US)
Pages (from-to)475-488
Number of pages14
JournalPET Clinics
Volume12
Issue number4
DOIs
StatePublished - Oct 1 2017

Keywords

  • Molecular targeted therapy
  • PET
  • PET/CT
  • Skeletal sarcoma
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma'. Together they form a unique fingerprint.

  • Cite this